Impedimed Limited · ASX:IPD
Impedimed — Shareholder Meeting (November 2024)
15 slides from Impedimed's shareholder meeting presentation, November 2024
Slide 1: Forging a new Standard of Care
ImpediMed Limited 2024 Annual General Meeting Forging a new Standard of Care Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2024 ImpediMed Limited. 1
Slide 2: Agenda
Agenda ImpediMed – FY24 Annual General Meeting Review - FY24 Financials Strategy - Focus on accelerating sales and controlling costs First application - Breast Cancer Related Lymphoedema (BCRL) New Team to execute Key Forward Indicators Value proposition
Slide 3: Core business revenue and ARR improving
Core business revenue and ARR improving Overall revenues down due to cessation of Astra Zeneca clinical trial FY24 Full-Year Results Total SOZO Core SOZO Core Number of patient revenue1 Business2 revenue Business ARR tests conducted $10.3 million $9.7 million $11.0 million 250,000 9% vs FY23 14% vs
Slide 4: SOZO Core Business growth driven by US up 14%
SOZO Core Business growth driven by US up 14% Global revenue by category Global revenue by geography 11.3 11.3 10.6 10.3 10.6 10.3 2.0 0.1 2.0 0.1 0.5 0.9 3.3 0.8 3.3 1.0 FY24 SOZO Core Business 0.7 1.1 revenue up 14% vs. FY23. A $ millions A $ millions 9.7 9.3 US business 90% of revenue. 8.5 8.3 6.
Slide 5: ARR is up 18% vs. FY23, and continues to show long term growth
ARR is up 18% vs. FY23, and continues to show long term growth SOZO Core Business ARR1 22% 11.0 3-year CAGR2 10.1 9.3 ARR up 18% vs. FY23 ($9.3m) 8.2 7.3 6.7 6.1 A$ millions FY21 H2 FY22 H1 FY22 H2 FY23 H1 FY23 H2 FY24 H1 FY24 H2 1.Annual Recurring Revenue (ARR) represents the amount of revenue reas
Slide 6: Patient testing grew 24% as a 3-year CAGR
Patient testing grew 24% as a 3-year CAGR SOZO patient tests (000s) 24% 3-year CAGR1 18% growth vs. FY23 154 126 An important driver of renewals 92 70 40 96 17 85 62 72 47 32 8 2 FY18 FY19 FY20 FY21 FY22 FY23 FY24 New Follow up 1.Compound Annual Growth Rate (based on annual totals). 6
Slide 7: Immediate strategy
Immediate strategy Execute to breakeven with a focus of sales, marketing and clinical execution in BCRL 12-Month Priorities Next 12 months: Execute towards break even July 2025 Next 1-2 years: Innovate and expand GOAL 1 GOAL 2 GOAL 3 GOAL 4 GOAL 5 BCRL sales World-class customer Progress to break ev
Slide 8: Forging a new Standard of Care for Breast Cancer Survivorship
Forging a new Standard 4M 82% of Care for Breast • US breast cancer Breast cancer patients are at survivors1 risk of arm lymphedema due to Cancer Survivorship 310k Newly diagnosed US their treatment5 breast cancer patients every • Lymph node surgery year1 • Radiation therapy • Taxane-based chemoth
Slide 9: SOZO BIS: All elements in place to forge the new Standard of Care
SOZO BIS: All elements in place to forge the new Standard of Care $600m Positive Global Clinical Trial BCRL TAM 1200 patient trial: Statistically Significant Widespread & Increasing US Payor Coverage Lower Progression to Chronic Lymphoedema1 FDA cleared • 23 US States now at Critical Mass (>80% cove
Slide 10: SOZO BCRL: Replaces time consuming SOC with early, objective & fast detection
SOZO BCRL: Replaces time consuming SOC with early, objective & fast detection for Breast Cancer Related Lymphoedema Current Standard of Care (SOC) Bioimpedance Spectroscopy (BIS) – FDA-cleared, Clinically Validated, Subjective or Time-Consuming Guideline Supported, Reimbursed, Early, Objective & Fas
Slide 11: ImpediMed Board – New Team with Global Experience
ImpediMed Board – New Team with Global Experience Governance Project delivery Culture Performance Non-Executive Directors Executive Directors Global Company Experience • Pfizer • Google • IBM Christine Janelle Delaney Fiona Bones Andrew Grant Dr Parmjot Bains McGregor Grant • McKinsey Emmanu
Slide 12: New World Class Executive team
New World Class Executive team US healthcare market Medtech commercialisation Sales execution Creating long-term value Executive Directors Executives Dr Parmjot Bains McGregor Grant Dr Steven Chen Tim Benkovic Julie Kuhlken Aaron Ogilvie Ashley Munoz Dennis Schlaht CEO / Managing CF&OO / Chi
Slide 13: Key forward looking metrics improving
Key forward looking metrics improving Q1 FY25 Pipeline Metrics and New Payor Coverage Metrics FY25 Q1 Sales Pipeline Updated Mid Q2 FY 25 585 devices Critical Mass States1 34% increase vs Q4 FY24 23 States +7 vs Q1 FY25 Q1 FY 25 NAPBC Standard Inclusion Updated Mid Q2 FY 25 SOZO at 143/570 254.7m Ac
Slide 14: Momentum Continues
Momentum Continues Forward sales indicators improve and TCV momentum returns U.S. SOZO Units Sales Pipeline1 SOZO Core Business Quarterly TCV Sales Pipeline up 100% Q1 FY25 Pipeline up 34% vs. Q4 FY24 Record quarterly increase in TCV2 1.Total Opportunity Pipeline represents SOZO units in pipeline at
Slide 15: The Value Proposition
The Value Proposition Multiple Regulatory Clearances Lymphoedema Heart Failure Reimbursement Renal Failure 73% of US Body Comp Successful Insured Lives covered Global RCT Lymphoedema Critical mass prevention coverage in 23 US States Guideline and Initial TAM Standard $600M Inclusion Multi-Applicatio